{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:01:32Z","timestamp":1792839692311,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AUSL, Local Health Agency of Ferrara, Italy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Hepatitis C virus (HCV) is a worldwide health hazard, and in chronic form (nowadays affecting 50\u00a0million people \u2013 World Health Organization data) can be lethal. To forestall it, preventive screening is a mandatory approach. Since 2021, Italy conducts a national-wide screening program to eliminate the virus from its population. The team perfected an innovative method throughout the period between 2022 and 2023, to answer that medical necessity and map HCV genotypes. The medical protocol has introduced a dedicated double invitation model for the adherents, with consequential pre-prepared medical consumables allocated. The population was divided in three separate groups: born between 1969 and 1989, addiction services, and prison. Two screening levels were carried out: anti-HCV antibodies (indirect chemiluminescence immunoassay) and quantitative HCV RNA reverse transcription. 51,283 adherents were registered: 447 resulted positive to the first screening round, and 88 to the second (393 and 77 patients respectively from population born between 1969 and 1989). The medical protocol introduced allowed to substantially increase patients and medical staff compliance to HCV screening (adherence: 51.83%, the highest in Italy). HCV genotypes\u2019 distribution was mapped by patients\u2019 age, biological sex and origin over five groups comprehending subtypes 1a(35.06% of the positive population), 1b(27.27%), 2a\/2c(10.39%), 3a(22.08%), 4a\/4c\/4d(5.19%).<\/jats:p>","DOI":"10.1038\/s41598-025-92654-w","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T07:35:31Z","timestamp":1741419331000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Italian screening protocol and genotypes characterization for HCV elimination (2022\u20132023) in Ferrara\u2019s province: a real-world study"],"prefix":"10.1038","volume":"15","author":[{"given":"Nicol\u00f2","family":"Landini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Chiericati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Trombini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Zanforlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Palmonari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"92654_CR1","unstructured":"Hepatitis C. World Health Organization, Accessed 13 November, 2024; https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Published 9 April, 2024."},{"key":"92654_CR2","unstructured":"Hepatitis C Annual Epidemiological Report for 2020 surveillance report, ECDC European Centre for Diseases prevention and Control."},{"issue":"4","key":"92654_CR3","first-page":"249","volume":"45","author":"LA Kondili","year":"2022","unstructured":"Kondili, L. A. et al. Prevalence of hepatitis C virus estimates of undiagnosed individuals in different Italian regions: A mathematical modelling approach by route of transmission and fibrosis progression with results up to January 2021. New Microbiol. 45(4), 249\u2013259 (2022).","journal-title":"New Microbiol."},{"issue":"1","key":"92654_CR4","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/S1665-2681(19)31720-X","volume":"9","author":"A Soza","year":"2010","unstructured":"Soza, A., Riquelme, A. & Arrese, M. Routes of transmission of hepatitis C virus. Ann. Hepatol. 9(1), S30\u2013S33 (2010).","journal-title":"Ann. Hepatol."},{"key":"92654_CR5","doi-asserted-by":"crossref","unstructured":"Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org; Hughes, B.L., Page, C.M. & Kuller, J.A. Hepatitis C in pregnancy: Screening, treatment, and management. Am. J. Obstet. Gynecol. 217(5), B2\u2013B12 (2017).","DOI":"10.1016\/j.ajog.2017.07.039"},{"key":"92654_CR6","unstructured":"Cirrhosis of the Liver. Cleveland Clinic, accessed 13 November 2024; https:\/\/my.clevelandclinic.org\/health\/diseases\/15572-cirrhosis-of-the-liver\/. Published 26 July 2023."},{"key":"92654_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2024.101423","volume":"67","author":"F Fiehn","year":"2024","unstructured":"Fiehn, F., Beisel, C. & Binder, M. Hepatitis C virus and hepatocellular carcinoma: Carcinogenesis in the era of direct-acting antivirals. Curr. Opin. Virol. 67, 101423 (2024).","journal-title":"Curr. Opin. Virol."},{"key":"92654_CR8","unstructured":"Le terapie per curare l\u2019epatite C. EPAC, accessed 13 November, 2024; https:\/\/www.epac.it\/patologie\/nuove-terapie\/."},{"key":"92654_CR9","unstructured":"Malattie Infettive \u2013 Epatite C \u2013 Terapia. Ministero Della Salute, accessed November 13, 2024; https:\/\/www.salute.gov.it\/portale\/malattieInfettive\/dettaglioSchedeMalattieInfettive.jsp?lingua=italiano&id=118&area=Malattie%20infettive&menu=indiceAZ&tab=6\/. Published 27 July, 2023."},{"key":"92654_CR10","unstructured":"Cos\u2019\u00e8 Sofosbuvir\/Velpatasvir. EPAC, accessed 13 November, 2024; https:\/\/www.epatitec.info\/terapie\/terapia-sofosbuvir-velpatasvir\/."},{"issue":"3","key":"92654_CR11","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1177\/1060028019877128","volume":"54","author":"J Huff","year":"2020","unstructured":"Huff, J. & Andersen, R. Glecaprevir\/Pibrentasvir: The first 8-week, pangenotypic HCV treatment regimen for patients 12 years of age and older. Ann. Pharmacother. 54(3), 262\u2013276 (2020).","journal-title":"Ann. Pharmacother."},{"key":"92654_CR12","unstructured":"Table 1 - Confirmed HCV genotypes\/subtypes. ICTV, accessed 13 November, 2024; https:\/\/ictv.global\/sg_wiki\/flaviviridae\/hepacivirus\/table1\/. Published March, 2023."},{"key":"92654_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hep.27259","volume":"61","author":"JP Messina","year":"2015","unstructured":"Messina, J. P. et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61, 77\u201387 (2015).","journal-title":"Hepatology"},{"issue":"1","key":"92654_CR14","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","volume":"61","author":"E Gower","year":"2014","unstructured":"Gower, E. et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol. 61(1), S45\u2013S57 (2014).","journal-title":"J. Hepatol."},{"key":"92654_CR15","doi-asserted-by":"publisher","DOI":"10.2174\/18742858-v16-e2205300","author":"D Zago","year":"2022","unstructured":"Zago, D. et al. Circulating genotypes of hepatitis C virus in italian patients before and after the application of wider access criteria to HCV treatment. Open Microbiol. J. https:\/\/doi.org\/10.2174\/18742858-v16-e2205300 (2022).","journal-title":"Open Microbiol. J."},{"issue":"3","key":"92654_CR16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/jmv.20376","volume":"76","author":"F Ansaldi","year":"2005","unstructured":"Ansaldi, F. et al. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J. Med. Virol. 76(3), 327\u2013332 (2005).","journal-title":"J. Med. Virol."},{"key":"92654_CR17","unstructured":"Epatite C, al via in Emilia-Romagna lo screening gratuito. Regione Emilia Romagna - Salute. Epatite C, al via in Emilia-Romagna lo screening gratuito\/, accessed 13 Nov, 2024. Published January 25, 2022."},{"key":"92654_CR18","unstructured":"Epatite C, la Regione conferma anche per il 2023 lo screening gratuito per i nati dal 1969 al 1989. Regione Emilia Romagna \u2013 Salute, Epatite C, la Regione conferma anche per il 2023 lo screening gratuito per i nati dal 1969 al 1989\/, accessed 13 November, 2024. Published 14 February, 2023."},{"key":"92654_CR19","unstructured":"Quotidianosanit\u00e0.it \u2013 Studi e Analisi - Epatite C. In Italia ci sono ancora 380mila sieropositivi. Ecco perch\u00e9 dobbiamo accelerare lo screening, accessed 13 November, 2024; https:\/\/www.quotidianosanita.it\/studi-e-analisi\/articolo.php?articolo_id=100132. Published 18 November, 2021."},{"key":"92654_CR20","unstructured":"DECRETO 14\/05\/2021, \u201cEsecuzione dello screening nazionale per l\u2019eliminazione del virus dell\u2019HCV.\u201d (21A04075) (GU Serie Generale n.162 del 08-07-2021), accessed 13 November, 2024. https:\/\/www.gazzettaufficiale.it\/eli\/id\/2021\/07\/08\/21A04075\/sg\/."},{"key":"92654_CR21","unstructured":"Viral Hepatitis and Liver Disease - Laboratory Tests - Hepatitis C. U.S. Department of Veteran Affairs, accessed 13 November, 2024. https:\/\/www.hepatitis.va.gov\/hcv\/screening-diagnosis\/laboratory-tests.asp\/."},{"issue":"1","key":"92654_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jviromet.2005.09.009","volume":"133","author":"A Yaari","year":"2006","unstructured":"Yaari, A. et al. Detection of HCV salivary antibodies by a simple and rapid test. J. Virol. Methods 133(1), 1\u20135 (2006).","journal-title":"J. Virol. Methods"},{"issue":"1","key":"92654_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0022-2143(98)90028-2","volume":"132","author":"M de Medina","year":"1998","unstructured":"de Medina, M. et al. Detection of anti-hepatitis C virus antibodies in patients undergoing dialysis by utilizing a hepatitis C virus 3.0 assay: Correlation with hepatitis C virus RNA. J. Lab. Clin. Med. 132(1), 73\u201375 (1998).","journal-title":"J. Lab. Clin. Med."},{"key":"92654_CR24","unstructured":"Sonal Kumar, M. D. Epatite, C, Cronica. M. S. D. Accessed 13 November, 2024; https:\/\/www.msdmanuals.com\/it-it\/professionale\/malattie-del-fegato-e-delle-vie-biliari\/epatite\/epatite-c-cronica\/. Published August, 2022."},{"key":"92654_CR25","unstructured":"Screening dell\u2019infezione da HCV in Emilia-Romagna. Regione Emilia Romagna \u2013 Salute, Accessed 13 November, 2024; https:\/\/salute.regione.emilia-romagna.it\/notizie\/regione\/2023\/novembre\/epatite_c_tabella_riepilogativa_i_semestre_2023.pdf\/. Published August, 2022."},{"key":"92654_CR26","doi-asserted-by":"crossref","unstructured":"Barnett, N. W. & Francis, P. S. CHEMILUMINESCENCE|Overview. Editor(s): Worsfold P, Townshend A, Poole C. Encyclopedia of Analytical Science (Second Edition), Elsevier, 506\u2013511 (2005).","DOI":"10.1016\/B0-12-369397-7\/00069-8"},{"key":"92654_CR27","doi-asserted-by":"crossref","unstructured":"Jalali, M., Zaborowska, J. & Jalali, M. Chapter 1 - The Polymerase Chain Reaction: PCR, qPCR, and RT-PCR, Editor(s): Jalali M, Saldanha FYL, Jalali M. Basic Science Methods for Clinical Researchers, Academic Press, 1\u201318 (2017).","DOI":"10.1016\/B978-0-12-803077-6.00001-1"},{"issue":"16","key":"92654_CR28","first-page":"759","volume":"20","author":"S Gallagher","year":"2008","unstructured":"Gallagher, S. & Chakavarti, D. Immunoblot analysis. J. Vis. Exp. 20(16), 759 (2008).","journal-title":"J. Vis. Exp."},{"issue":"7","key":"92654_CR29","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3390\/biology12070997","volume":"12","author":"H Satam","year":"2023","unstructured":"Satam, H. et al. Next-generation sequencing technology: Current trends and advancements. Biology 12(7), 997 (2023).","journal-title":"Biology"},{"issue":"4","key":"92654_CR30","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.gtc.2015.07.013","volume":"44","author":"T Asselah","year":"2015","unstructured":"Asselah, T. & Bourli\u00e8re, M. Hepatitis C virus: Current and evolving treatments for genotype 4. Gastroenterol. Clin. North Am. 44(4), 859\u2013870 (2015).","journal-title":"Gastroenterol. Clin. North Am."},{"issue":"4","key":"92654_CR31","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/hep.22127","volume":"47","author":"SM Kamal","year":"2008","unstructured":"Kamal, S. M. & Nasser, I. A. Hepatitis C genotype 4: What we know and what we don\u2019t yet know. Hepatology 47(4), 1371\u20131383 (2008).","journal-title":"Hepatology"},{"key":"92654_CR32","unstructured":"Cittadini stranieri 2023 - provincia di Ferrara. TuttItalia, accessed 13 November, 2024; https:\/\/www.tuttitalia.it\/emilia-romagna\/provincia-di-ferrara\/statistiche\/cittadini-stranieri-2023\/. Published 1 January, 2023."},{"key":"92654_CR33","unstructured":"Screening nazionale HCV - Regioni: al via i piani regionali. abbviePRO, accessed 13 November, 2024; https:\/\/www.abbviepro.com\/it\/it\/virology\/screening-nazionale-hcv\/legge-e-delibere-regionali.html. Published 1 January, 2023."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92654-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92654-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92654-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T07:35:38Z","timestamp":1741419338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92654-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["92654"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-92654-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"28 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All research was conducted in accordance with both the Declarations of Helsinki and Istanbul. The work subject is an Italian national-wide screening program, not a clinical trial, therefore not only the connection between patients and personal data cannot be traced and no patient consent was required, but said data are part of the evolution of the Information Obligation for the NSIS (New sanitary informative system) and SIAD flux (Homecare Assistance) in the Healthcare Environment required by the relevant national bodies (Region, Ministries, Corte dei Conti) for statistical analysis. Regulations of said protocol are fetchable in the correlated Decree-Laws, available indefinitely at:","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate and consent for publication"}}],"article-number":"8087"}}